Unintentional sulfonylurea toxicity due to a drug–drug interaction: a case report
BMC Research Notes, 2018 Background Sulfonylureas are widely used for type 2 diabetes mellitus, but these medications carry a risk of hypoglycemia. Drug–drug interactions that inhibit sulfonylurea metabolism and thus increase systemic exposure can cause unintentional ...
Keith Gunaratne +2 more
doaj +1 more source
Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport [PDF]
, 1994 . Lipoprotein lipase (LPL) and glycolipidanchored cAMP-binding ectoprotein (Gcel) are modified by glycosyl-phosphatidylinositol (GPI) in rat adipocytes, however, the linkage is potentially unstable. Incubation of the cells with either insulin (0.1-30 nM)
Bandlow, Wolfhard +3 more
core +3 more sources
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +9 more sources
Some doubts about the mantra on the deleterious cardiovascular effects of sulfonylureas [PDF]
, 2017 [No abstract ...
Prudente, Sabrina, Trischitta, Vincenzo
core +1 more source
Cantu syndrome–associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms [PDF]
, 2018 The complex disorder Cantu syndrome (CS) arises from gainof-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively. Recent reports indicate that such mutations
Grange, Dorothy K. +7 more
core +2 more sources
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study [PDF]
Endocrinology and MetabolismBackground Inconsistent results have been reported regarding the association between the use of antidiabetic drugs and the clinical outcomes of coronavirus disease 2019 (COVID-19). This study aimed to investigate the effect of antidiabetic drugs on COVID-
Han Na Jang +5 more
doaj +1 more source
Medicina, 2022 Background and objectives: In the last couple of years, pharmacological management of patients with type 2 diabetes mellitus (T2DM) have been markedly renewed. The aim of this study was to analyse the changes in prescribing patterns of antidiabetic drugs
György Jermendy +6 more
doaj +1 more source
Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus [PDF]
, 2006 Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Balkau +33 more
core +1 more source
MODY3 in the child with type 2 diabetes mellitus phenotype: case report
Сахарный диабет, 2013 MODY is a heterogeneous group of diseases that stem from certain genetic mutations and are characterized by beta-cell dysfunction, early clinical onset (before the age of 25) and autosomal dominant inheritance.
Tamara Leonidovna Kuraeva +4 more
doaj +1 more source